ガバペンチン市場：製品別、投与経路別、薬効別、用途別、流通チャネル別-2025-2030年世界予測

ガバペンチン市場は2023年に22億2,000万米ドルと評価され、2024年には23億2,000万米ドルに達すると予測され、CAGR 4.38%で成長し、2030年には30億米ドルになると予測されています。

抗けいれん薬であるガバペンチンは、医薬品市場において幅広い範囲をカバーしており、主に神経障害性疼痛やけいれんの治療に使用されています。その必要性は、神経関連の疼痛管理に有効であることから生じ、慢性疼痛疾患やてんかん患者のQOL向上に貢献しています。ガバペンチンの用途はこれらの主要用途にとどまらず、不安障害やレストレスレッグス症候群の管理といった適応外使用も含まれるため、最終用途の範囲が広がっています。市場の洞察によると、神経障害性疼痛疾患の有病率の増加と老年人口の増加が主要な成長促進要因であることが明らかになっています。さらに、非オピオイド性疼痛管理ソリューションに対する需要の高まりが、ガバペンチンの市場での存在感をさらに高めています。ガバペンチンの治療用途の拡大に焦点を当てた調査の増加により、製薬会社はより幅広い用途を探索する臨床試験に投資できるようになり、市場内の機会が生まれています。しかし、市場は代替療法との競合、副作用の可能性、適応外使用に関する規制当局の監視、ブランド品に影響を及ぼす特許切れなどの課題に直面しています。また、従来とは異なる使用法が承認されないと市場拡大が阻害される可能性があるため、規制環境も制約となります。このような障害を克服するために、精密医療や遺伝子プロファイリングなどの革新的な調査により、特定の治療ニーズを持つ新たな患者層が発見され、ターゲットを絞った製剤が推進される可能性があります。また、徐放性製剤や新規の併用療法など、送達メカニズムの進歩により、患者のコンプライアンスと有効性が向上する可能性もあります。さらに、患者のニーズをよりよく理解し、ガバペンチンの使用を最適化するためのヘルスケアプロバイダーとのパートナーシップは、市場浸透をさらに促進することができます。そのため、疼痛管理における継続的な開発、規制の最新情報、競合の動向を常に把握することが重要です。テクノロジーの統合によりデータを活用することで、患者の嗜好に関する洞察を企業に提供し、ガバペンチンの市場ポジションを向上させ、持続可能な成長を確保するためのマーケティング戦略を可能にします。このような市場のダイナミックな性質から、新たな機会を効果的に活用するためには、戦略的な俊敏性と調査主導型のイノベーションに注力する必要があります。

市場力学：急速に進化するガバペンチン市場の主要市場インサイトを公開

ガバペンチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疼痛および関連疾患の増加により、効果的な治療オプションへのニーズが高まる
  • ガバペンチンの多剤併用型疼痛管理レジメンへの統合による臨床現場での採用促進
  • 必要不可欠な医薬品を入手しやすくするための政府の取り組みとヘルスケア政策
• 市場抑制要因
  • 代替療法や偽造品、安価な医薬品との競合
• 市場機会
  • ペットや家畜の疼痛管理を目的とした獣医療におけるガバペンチンのニーズの高まり
  • 線維筋痛症および関連する慢性疼痛症候群の治療薬としてのガバペンチンの登場
  • ガバペンチンをベースとした併用療法の開発による神経疾患における治療効果の向上
• 市場の課題
  • 潜在的な副作用や誤用に対する懸念の高まり

ポーターの5つの力：ガバペンチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ガバペンチン市場における外部からの影響の把握

外部マクロ環境要因は、ガバペンチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ガバペンチン市場における競合情勢の把握

ガバペンチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスガバペンチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ガバペンチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ガバペンチン市場における成功への道筋を描く

ガバペンチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疼痛および関連疾患の発生率の上昇により、効果的な治療法の必要性が高まっている
    • マルチモーダル疼痛管理レジメンにガバペンチンを統合し、臨床現場での採用を促進する
    • 必須医薬品の入手性と手頃な価格を重視する政府の取り組みとヘルスケア政策
  • 抑制要因
    • 代替療法や偽造医薬品、安価な医薬品との競合
  • 機会
    • ペットや家畜の疼痛管理のための獣医学におけるガバペンチンの需要の高まり
    • 線維筋痛症および関連する慢性疼痛症候群の治療における重要な薬剤としてのガバペンチンの出現
    • 神経疾患の治療効果を高めるガバペンチンをベースとした併用療法の開発
  • 課題
    • 潜在的な副作用や誤用に対する懸念が高まる
• 市場セグメンテーション分析
  • 製剤：便利で簡単な選択肢のため、カプセルが好まれる
  • 用途：神経活動を安定させ、発作頻度を減らすために、部分発作の補助療法として広く利用されています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ガバペンチン市場：製品別

• カプセル
• 錠剤

第7章 ガバペンチン市場：投与経路別

• オーラル
• 非経口

第8章 ガバペンチン市場薬別

• ブランド
• ジェネリック

第9章 ガバペンチン市場：用途別

• 不安
• てんかん
• 神経障害性疼痛
• むずむず脚症候群

第10章 ガバペンチン市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカのガバペンチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のガバペンチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのガバペンチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ストライド・ファーマが神経科治療薬で米国FDAの承認を取得ガバペンチン
  • ロータスとアダルボが韓国でガバペンチンERを発売
• 戦略分析と提言

企業一覧

• 1. AVEFLOR, a. s.
• 2. BD Custom Manufacturing
• 3. Capital Resin Corporation
• 4. Chemplast Sanmar Limited
• 5. Con-Tech International.
• 6. Custom Manufacturing Corporation
• 7. Custom Manufacturing Solutions
• 8. Dassault Systemes
• 9. Dassault Systemes S.E.
• 10. East West Manufacturing, LLC
• 11. Evonik Industries AG
• 12. Formlabs Inc.
• 13. Ganesh Group of Industries
• 14. Grand Prix International PLC
• 15. Hexagon AB
• 16. Monroe Engineering, LLC
• 17. Promega Corporation.
• 18. Protocase Incorporated
• 19. RAS Polska Sp. z o.o.
• 20. Sartorius AG
• 21. SHENZHEN WEIKE RAPID PROTOTYPING TECHNOLOGY CO. LTD
• 22. Siemens AG
• 23. Thomas Swan & Co. Ltd.
• 24. VWR International, LLC.

LIST OF FIGURES

• FIGURE 1. GABAPENTIN MARKET RESEARCH PROCESS
• FIGURE 2. GABAPENTIN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GABAPENTIN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GABAPENTIN MARKET DYNAMICS
• TABLE 7. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GABAPENTIN MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GABAPENTIN MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEGS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. CANADA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. CANADA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. CANADA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. CANADA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. CHINA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. CHINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. CHINA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 71. CHINA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. CHINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. INDIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. INDIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. INDIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 76. INDIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. INDIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. ITALY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. ITALY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 161. ITALY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 162. ITALY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. ITALY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. POLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. POLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 181. POLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 182. POLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. POLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. QATAR GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 185. QATAR GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. QATAR GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 187. QATAR GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. QATAR GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 234. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 235. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2023

The Gabapentin Market was valued at USD 2.22 billion in 2023, expected to reach USD 2.32 billion in 2024, and is projected to grow at a CAGR of 4.38%, to USD 3.00 billion by 2030.

Gabapentin, an anticonvulsant medication, has a broad scope within the pharmaceutical market, predominantly used to treat neuropathic pain and seizures. Its necessity arises from its effectiveness in managing nerve-related pain conditions, contributing to quality of life improvements for individuals with chronic pain disorders and epilepsy. The application of gabapentin extends beyond these primary uses, also encompassing off-label uses such as managing anxiety disorders and restless leg syndrome, thus widening its end-use scope. Market insights reveal that the growing prevalence of neuropathic pain conditions and the increasing geriatric population are key growth drivers. Additionally, the rise in demand for non-opioid pain management solutions further propels gabapentin's market presence. Opportunities within the market are emerging from the increasing research focused on expanding gabapentin's therapeutic applications, allowing pharmaceutical companies to invest in clinical trials exploring broader uses. However, the market faces challenges, including competition from alternative therapies, potential side effects, regulatory scrutiny concerning off-label uses, and patent expirations impacting branded versions. Regulatory environments also pose limitations, as non-approval for non-traditional uses could stymie market expansion. To navigate these obstacles, innovative areas of research such as precision medicine and genetic profiling could uncover new patient segments with specific therapeutic needs, driving targeted gabapentin formulations. Advancing delivery mechanisms, such as sustained-release formats or novel combination therapies, could also enhance patient compliance and efficacy. Moreover, partnerships with healthcare providers to better understand patient needs and optimize gabapentin use can further market penetration. Therefore, staying attuned to continuous developments in pain management, regulatory updates, and competitive activities is crucial. Harnessing data through technology integration could offer businesses insights into patient preferences, enabling tailored marketing strategies that enhance gabapentin's market position while ensuring sustainable growth. This dynamic nature of the market necessitates strategic agility and a focus on research-driven innovation for leveraging emerging opportunities effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gabapentin Market

The Gabapentin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of chronic pain and related conditions increasing the need for effective treatment options
  • Integration of gabapentin in multimodal pain management regimens promoting its adoption in clinical practice
  • Government initiatives and healthcare policies favoring the availability and affordability of essential medications
• Market Restraints
  • Competition from alternative therapies and counterfeit and cheap-quality drugs
• Market Opportunities
  • Growing need for gabapentin in veterinary medicine for pain management in pets and livestock
  • Emergence of gabapentin as a key drug in the treatment of fibromyalgia and related chronic pain syndromes
  • Development of gabapentin-based combination therapies for enhanced treatment efficacy in neurological disorders
• Market Challenges
  • Increasing concerns over potential side effects and misuse

Porter's Five Forces: A Strategic Tool for Navigating the Gabapentin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gabapentin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gabapentin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gabapentin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gabapentin Market

A detailed market share analysis in the Gabapentin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gabapentin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gabapentin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gabapentin Market

A strategic analysis of the Gabapentin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gabapentin Market, highlighting leading vendors and their innovative profiles. These include AVEFLOR, a. s., BD Custom Manufacturing, Capital Resin Corporation, Chemplast Sanmar Limited, Con-Tech International., Custom Manufacturing Corporation, Custom Manufacturing Solutions, Dassault Systemes, Dassault Systemes S.E., East West Manufacturing, LLC, Evonik Industries AG, Formlabs Inc., Ganesh Group of Industries, Grand Prix International PLC, Hexagon AB, Monroe Engineering, LLC, Promega Corporation., Protocase Incorporated, RAS Polska Sp. z o.o., Sartorius AG, SHENZHEN WEIKE RAPID PROTOTYPING TECHNOLOGY CO. LTD, Siemens AG, Thomas Swan & Co. Ltd., and VWR International, LLC..

Market Segmentation & Coverage

This research report categorizes the Gabapentin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Capsule and Tablet.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on Medication, market is studied across Branded and Generic.
• Based on Application, market is studied across Anxiety, Epilepsy, Neuropathic Pain, and Restless Legs Syndrome.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of chronic pain and related conditions increasing the need for effective treatment options
    • 5.1.1.2. Integration of gabapentin in multimodal pain management regimens promoting its adoption in clinical practice
    • 5.1.1.3. Government initiatives and healthcare policies favoring the availability and affordability of essential medications
  • 5.1.2. Restraints
    • 5.1.2.1. Competition from alternative therapies and counterfeit and cheap-quality drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing need for gabapentin in veterinary medicine for pain management in pets and livestock
    • 5.1.3.2. Emergence of gabapentin as a key drug in the treatment of fibromyalgia and related chronic pain syndromes
    • 5.1.3.3. Development of gabapentin-based combination therapies for enhanced treatment efficacy in neurological disorders
  • 5.1.4. Challenges
    • 5.1.4.1. Increasing concerns over potential side effects and misuse
• 5.2. Market Segmentation Analysis
  • 5.2.1. Formulation: High preference for capsules due to convenient and straightforward option
  • 5.2.2. Application : Widely utilized as an adjunct therapy for partial seizures to stabilize neuronal activity and reduce seizure frequency
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Gabapentin Market, by Product

• 6.1. Introduction
• 6.2. Capsule
• 6.3. Tablet

7. Gabapentin Market, by Route of Administration

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parenteral

8. Gabapentin Market, by Medication

• 8.1. Introduction
• 8.2. Branded
• 8.3. Generic

9. Gabapentin Market, by Application

• 9.1. Introduction
• 9.2. Anxiety
• 9.3. Epilepsy
• 9.4. Neuropathic Pain
• 9.5. Restless Legs Syndrome

10. Gabapentin Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Gabapentin Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Gabapentin Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Gabapentin Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Strides Pharma receives USFDA approval for neurology medication Gabapentin
  • 14.3.2. Lotus and Adalvo launch Gabapentin ER in South Korea
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AVEFLOR, a. s.
• 2. BD Custom Manufacturing
• 3. Capital Resin Corporation
• 4. Chemplast Sanmar Limited
• 5. Con-Tech International.
• 6. Custom Manufacturing Corporation
• 7. Custom Manufacturing Solutions
• 8. Dassault Systemes
• 9. Dassault Systemes S.E.
• 10. East West Manufacturing, LLC
• 11. Evonik Industries AG
• 12. Formlabs Inc.
• 13. Ganesh Group of Industries
• 14. Grand Prix International PLC
• 15. Hexagon AB
• 16. Monroe Engineering, LLC
• 17. Promega Corporation.
• 18. Protocase Incorporated
• 19. RAS Polska Sp. z o.o.
• 20. Sartorius AG
• 21. SHENZHEN WEIKE RAPID PROTOTYPING TECHNOLOGY CO. LTD
• 22. Siemens AG
• 23. Thomas Swan & Co. Ltd.
• 24. VWR International, LLC.